Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Immunovia AB's Revenue for the
three
months ended in Mar. 2026 was $0.04 Mil. Immunovia AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.01 Mil.
Hence, Immunovia AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.71.
Immunovia AB (OTCPK:IMMVF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Immunovia AB Receivables Turnover Related Terms
Immunovia AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMVF vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Immunovia AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (IMMVF) has a Receivables Turnover of 5.71 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #18 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 8.9%.
Is Immunovia AB's Receivables Turnover too high?
Immunovia AB's current Receivables Turnover is 5.71. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Immunovia AB's value of 5.71 is 6.1% above this industry median. Based on the distribution chart, Immunovia AB ranks #18 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #18 out of 202 companies for Receivables Turnover. This places Immunovia AB in the top 9% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.38. Immunovia AB's value of 5.71 is 6.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovia AB's current Receivables Turnover of 5.71 is 6.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Receivables Turnover is 5.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Receivables Turnover of 5.71. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Receivables Turnover is 5.71 and 6.1% above the Medical Diagnostics & Research industry median of 5.38. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Receivables Turnover is 5.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
Receivables Turnover: 5.71
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
Industry Position: 6.1% above the Medical Diagnostics & Research median (#18 of 202)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score
Get the complete analysis for IMMVF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
